In this article:
What is Papillary Thyroid Cancer?
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for approximately 80% of all thyroid malignancies. It originates in the follicular cells of the thyroid gland, which are responsible for producing thyroid hormones. PTC is typically slow-growing but can spread to lymph nodes in the neck and, occasionally, to other parts of the body.
Papillary thyroid cancer is characterized by the growth of malignant cells in the thyroid’s follicular epithelium and the presence of papillae—small, finger-like projections in the cancerous tissue. It often presents as a painless nodule or lump in the thyroid region.
Subtypes
As one of the four main types of thyroid cancer, PTC has several subtypes (or variants). These include the:
- classic variant (also known as classical papillary carcinoma)
- follicular variant (which is not to be confused with follicular thyroid cancer)
- tall cell variant
- diffuse sclerosing variant
Each variant may have different clinical implications and prognostic factors.
Prevalence and Demographics
Papillary thyroid cancer is diagnosed more frequently in women than in men, with a higher incidence in individuals between the ages of 30 and 50. However, it can occur at any age. The incidence of PTC has been rising globally, partly due to enhanced detection methods.
Risk Factors for Papillary Thyroid Cancer
While the exact cause of PTC remains unknown, the two main risk factors are:
Genetic Factors
Certain genetic mutations, such as those in the BRAF, RET/PTC, and RAS genes, are associated with an increased risk of developing PTC. Family history of thyroid cancer or genetic syndromes like familial adenomatous polyposis (FAP) and Cowden syndrome can also elevate risk.
Radiation Exposures
Exposure to ionizing radiation, particularly during childhood, is a well-documented risk factor for PTC. This includes radiation therapy for other cancers and exposure from nuclear accidents or radiation fallout.
Symptoms of Papillary Thyroid Cancer
PTC is often asymptomatic in its early stages and is frequently discovered incidentally during imaging for unrelated conditions. When symptoms do occur, they may include:
- A lump in the neck: The most common symptom is a palpable lump or swelling in the neck.
- Difficulty swallowing or breathing: The tumor may press against your esophagus.
- Hoarseness or voice changes: This occurs if the tumor affects the nerves connected to the vocal cords.
- Neck pain: Pain can sometimes extend up to the ears.
- Swollen lymph nodes: Enlarged lymph nodes in the neck could indicate metastasis.
Diagnostic Procedures
- Physical Examination: Initial evaluation includes a thorough physical examination of the neck to detect lumps or enlarged lymph nodes.
- Imaging Studies
- Ultrasound: The primary imaging modality for evaluating thyroid nodules and guiding fine-needle aspiration biopsy.
- Radioiodine Scans: Used to determine the functional status of thyroid nodules.
- CT/MRI Scans: Occasionally used for more detailed anatomical information, particularly if there is concern about spread to nearby structures.
- Fine-Needle Aspiration (FNA) Biopsy: FNAB is a minimally invasive procedure used to extract cells from a thyroid nodule for microscopic examination. It is the gold standard for diagnosing thyroid malignancies.
- Molecular Testing: Testing for genetic mutations (e.g., BRAF, RAS, RET/PTC) can provide additional diagnostic and prognostic information.
Staging and Classification
The TNM staging system, developed by the American Joint Committee on Cancer (AJCC), is used to classify the extent of PTC. It considers the size of the tumor (T), involvement of lymph nodes (N), and presence of metastasis (M).
Age is also a significant factor in staging, with different thresholds for younger (under 55) and older (55 and older) patients.
Staging helps determine the appropriate treatment approach and predict the prognosis. Early-stage PTC typically has an excellent prognosis, while advanced stages may require more aggressive treatment.
Treatment Options
Treatment for PTC depends on the stage and extent of the cancer, as well as the patient’s overall health. Common treatment methods include:
Surgical Interventions
- Thyroidectomy: The removal of part or all of the thyroid gland is the primary treatment. Depending on the extent, this can be a partial or total thyroidectomy. A partial thyroidectomy may also be referred to as a hemi-thyroidectomy or lobectomy when one lobe of the thyroid gland is removed.
- Lymph Node Removal: If cancer has spread to nearby lymph nodes, these might also be removed.
Radioactive Iodine (RAI) Therapy
After surgery, RAI can be used to destroy any remaining thyroid tissue or metastatic cells. The thyroid cells absorb the radioactive iodine, which helps in targeting the cancerous cells specifically.
Thyroid Hormone Therapy
After total thyroidectomy, patients require lifelong hormone replacement therapy to maintain normal thyroid hormone levels and prevent hypothyroidism. This also helps suppress the production of TSH. This is important as advanced thyroid cancers are associated with high TSH levels.
Prognosis and Follow-up
Prognosis
The prognosis for PTC is generally excellent, with a 10-year survival rate exceeding 90% for most patients. Factors influencing prognosis include age, tumor size, extent of disease, and specific histological features. Younger patients and those with localized disease tend to have the best outcomes.
Follow-Up and Monitoring
Long-term follow-up is essential to monitor for recurrence, which can occur even decades after initial treatment. Follow-up typically includes:
- Physical examinations and neck ultrasounds to detect recurrences.
- Thyroglobulin testing: Thyroglobulin is a protein produced by thyroid tissue; its presence after thyroidectomy can indicate residual or recurrent disease.
- Whole-body radioiodine scans: Periodically used to detect metastatic disease.
Living with Papillary Thyroid Cancer
Psychological and Emotional Support
A diagnosis of PTC can have a significant emotional impact. It’s essential for patients to have access to psychological support, whether through counseling, support groups, or mental health professionals. This support can help patients cope with the stress and anxiety that often accompany a cancer diagnosis and treatment.
Support Groups and Resources
Support groups, both in-person and online, offer a platform for patients to share experiences, receive encouragement, and gain insights from others facing similar challenges. Organizations like the American Cancer Society and the Thyroid Cancer Survivors’ Association (ThyCa) provide valuable resources and support networks for patients and their families.
ThyForLife Health offers you an anonymous global community supporting all thyroid conditions, including all types of thyroid cancer. Currently, the community is available only in the English language. To join this community, download the ThyForLife app on the Apple App Store or Google PlayStore.
Key takeaways
- Papillary thyroid cancer, despite being the most common form of thyroid cancer, has a favorable prognosis due to its slow-growing nature and effective treatment options.
- Early detection, appropriate surgical management, and careful long-term monitoring are crucial for ensuring the best outcomes for patients.
- If you suspect any symptoms or have a family history of thyroid issues, it’s essential to consult a healthcare professional for timely evaluation and intervention.
